8F8X
 
 | | Crystal structure of Nb.X0 bound to the afucosylated human IgG1 fragment crystal form II | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Nb.X0, Uncharacterized protein DKFZp686C11235 | | Authors: | Goldgur, Y, Ravetch, J, Gupta, A, Kao, K, Oren, D. | | Deposit date: | 2022-11-22 | | Release date: | 2023-03-29 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (2.6 Å) | | Cite: | Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody.
Nat Commun, 14, 2023
|
|
8F8V
 | | Crystal structure of Nb.X0 | | Descriptor: | Nb.X0 | | Authors: | Goldgur, Y, Ravetch, J, Gupta, A, Kao, K, Andi, B. | | Deposit date: | 2022-11-22 | | Release date: | 2023-03-29 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (1.81 Å) | | Cite: | Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody.
Nat Commun, 14, 2023
|
|
8F8W
 | | Crystal structure of Nb.X0 bound to the afucosylated human IgG1 fragment crystal form I | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Nb.X0, afucosylated IgG1 fragment | | Authors: | Goldgur, Y, Ravetch, J, Gupta, A, Kao, K, Oren, D. | | Deposit date: | 2022-11-22 | | Release date: | 2023-03-29 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (2.71 Å) | | Cite: | Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody.
Nat Commun, 14, 2023
|
|
